NCT00884533View on ClinicalTrials.gov

QTc Study of Rosi XR in Healthy Volunteers

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Alzheimer's Disease

Interventions

DRUG

Rosi XR

Rosi XR

OTHER

Placebo

Placebo

DRUG

Moxifloxacin

400mg single dose

Trial Locations (2)

66211

GSK Investigational Site, Overland Park

SE1 1YR

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00884533 - QTc Study of Rosi XR in Healthy Volunteers | Biotech Hunter | Biotech Hunter